 InspireMD, Inc. NYSE American: NSPR, the developer of the CGuardTM Embolic Prevention System EPS for the prevention of stroke caused by carotid artery disease, today announced the pricing of an underwritten public offering of 22,222,200 units at a price to the public of 0.45 per unit. InspireMD expects to receive aggregate gross proceeds of approximately 10.0 million from the offering, assuming no exercise of the underwriters option to purchase additional securities. Each unit contains one share of common stock or common stock equivalent and one Series F warrant to purchase one share of common stock at an exercise price of 0.495 per share. 